CA2595330A1 - Spm 927 for add-on therapy of schizophrenia - Google Patents

Spm 927 for add-on therapy of schizophrenia Download PDF

Info

Publication number
CA2595330A1
CA2595330A1 CA002595330A CA2595330A CA2595330A1 CA 2595330 A1 CA2595330 A1 CA 2595330A1 CA 002595330 A CA002595330 A CA 002595330A CA 2595330 A CA2595330 A CA 2595330A CA 2595330 A1 CA2595330 A1 CA 2595330A1
Authority
CA
Canada
Prior art keywords
alkyl
use according
aryl
day
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002595330A
Other languages
English (en)
French (fr)
Inventor
Thomas Stoehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma Ag
Thomas Stoehr
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Schwarz Pharma Ag, Thomas Stoehr, Ucb Pharma Gmbh filed Critical Schwarz Pharma Ag
Publication of CA2595330A1 publication Critical patent/CA2595330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002595330A 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia Abandoned CA2595330A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843.1 2005-01-28
US60/647,410 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia
PCT/EP2006/000722 WO2006079547A2 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
CA2595330A1 true CA2595330A1 (en) 2006-08-03

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002595330A Abandoned CA2595330A1 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Country Status (12)

Country Link
EP (1) EP1841417A2 (es)
JP (1) JP2008528532A (es)
KR (1) KR20070096058A (es)
AR (1) AR057643A1 (es)
AU (1) AU2006208630B2 (es)
BR (1) BRPI0607043A2 (es)
CA (1) CA2595330A1 (es)
EA (1) EA015566B1 (es)
IL (1) IL183973A0 (es)
MX (1) MX2007009070A (es)
NO (1) NO20074361L (es)
WO (1) WO2006079547A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
MX2019007391A (es) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma

Also Published As

Publication number Publication date
BRPI0607043A2 (pt) 2009-08-04
AU2006208630A1 (en) 2006-08-03
WO2006079547A3 (en) 2006-09-21
NO20074361L (no) 2007-10-26
JP2008528532A (ja) 2008-07-31
WO2006079547A2 (en) 2006-08-03
AU2006208630B2 (en) 2011-09-29
EA200701594A1 (ru) 2008-02-28
AR057643A1 (es) 2007-12-12
KR20070096058A (ko) 2007-10-01
EP1841417A2 (en) 2007-10-10
IL183973A0 (en) 2008-12-29
EA015566B1 (ru) 2011-10-31
MX2007009070A (es) 2007-09-12

Similar Documents

Publication Publication Date Title
AU2006208630B2 (en) SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) Lacosamide for add-on therapy of psychosis
US10149845B2 (en) Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
JP6158376B2 (ja) 相乗的抗痙攣効果を有する医薬組成物
JP5038892B2 (ja) 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用
AU2018204831A1 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
ZA200705892B (en) SPM 927 for add-on therapy of schizophrenia
MXPA06014194A (es) Nuevo uso de compuestos peptidicos para tratar esclerosis lateral amiotrofica.
KR102608479B1 (ko) Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
MXPA06013300A (es) Uso novedoso de compuestos peptidicos para tratar discinesia.
WO2009018368A1 (en) Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BR112020004622A2 (pt) pridopidina para tratamento de discinesias induzidas por droga
US20150005252A1 (en) Combination therapy for the treatment of cancer
Seymour Drug interactions in dentistry
CA2461248C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US20220323435A1 (en) Composition and method for treatment of depression and psychosis in humans
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
EP1545546A1 (en) Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
UA53715C2 (uk) Інгредієнт лікарського засобу для лікування станів страху та напруженості та лікарський засіб, що має активність анксіолітика
KR20070030781A (ko) 근위축성 측삭 경화증의 치료를 위한 펩티드 화합물의신규한 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141219